April 23, 2025 4:38pm

Emphasizes that something will happen predictably as US equities and indexes surged as Trump calmed investors with tariff calming words and reversing Powell firing nerves

As cell and gene therapy equities came-off of its 4th upside session with a holiday in-between

Q1/25 earnings beginning to be posted: MDXG, 4/30 and ALNY, 5/1

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets. I put hours of effort to create reporting, while leveraging my 40 years of operating and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Wednesday’s, RegMed Investors’ (RMi) pre-open:  the tweets and tariff spins escalate optionality of markets and sector … https://www.regmedinvestors.com/articles/13890

Tuesday night’s RegMed Investors (RMi) Closing Bell: uncle algo and his electronic trading dwarfs are friends with benefits today … https://www.regmedinvestors.com/articles/13889

 

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), formerly Biostage (OTCQB: HRGN) “The latest, WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The Dow closed UP +419.59 points or +1.07%, the S&P closed UP +88.10 points or +1.67% while the Nasdaq close UP +407.63 points or +2.50%

  • Indexes surged on Wednesday on hopes that U.S.- China trade tensions could soon ease and Fed chair Powell keeps job

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • The purchasing manager surveys’ “flash” PMI for manufacturing hit a 16- month low with a reading of 50.7 for the month, just above the breakeven level of 50 for expansion. That was a slight increase from the upwardly revised 50.2 in March and better than the estimate for 49.5. On services, the index fell to 51.4, down from 54.5 and below the forecast for 52.8.

Wednesday’s advance/decline line opened with a positive 32 incliner, 1 decline and 2 flats ending with a positive close of 22 incliners, 10 decliners and 3 flats      

Metrics:  Wednesday, the IBB was +1.57%, the XBI was +1.43% while the VIX was down -2.15 points or -7.01% at 28.42

 

Q2/24 -April – 9 positive and 7 negative closes

  • Q1/25 – March, 10 positive and 12 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Wednesday’s Closing UP (10 of 22)

  • Alnylam Pharmaceuticals (ALNY +$5.22 after Tuesday’s +$4.00 after Monday’s -$1.81),
  • BioLife Solutions (BLFS +$2.46 after Tuesday’s +$0.74 after Monday’s -$0.76),
  • Blueprint Medicine (BPMC +$2.40 after Tuesday’s -$0.77 after Monday’s -$0.51),
  • Ultragenyx Pharmaceuticals (RARE +$1.40),
  • Lenz Therapeutics (LENZ +$1.16 after Tuesday’s +$1.68 after Monday’s +$0.29
  • Regenxbio (RGNX +$1.05 after Tuesday’s +$1.15 after Monday’s +$0.73)
  • Moderna (MRNA +$0.80 after Tuesday’s +$0.61 after Monday’s +$0.41),
  • Beam Therapeutics (BEAM +$0.74 after Tuesday’s +$0.89 after Monday’s +$1.24),
  • Vericel (VCEL +$0.63 after Tuesday’s -$1.45 after Monday’s -$0.36),
  • Mesoblast (MESO +$0.24),

Flat (3)

  • Editas Medicine (EDIT)
  • uniQure NV (QURE)
  • Homology Medicine (FIXX)

Wednesday’s Closing DOWN (10 of 10):

  • CRISPR Therapeutics (CRSP -$0.69 after Tuesday’s +$1.41),
  • bluebird bio (BLUE -$0.25),
  • Intellia Therapeutics (NTLA -$0.22),
  • Adverum Biotechnologies (ADVM -$0.11),
  • Sage Therapeutics (SAGE -$0.06),
  • Fate Therapeutics (FATE -$0.04)
  • Brainstorm Cell Therapeutics (BCLI -$0.039),
  • Sangamo Therapeutics (SGMO -$0.0222),
  • Agenus (AGEN -$0.02 after Tuesday’s +$0.56 after Monday’s +$0.23),
  • Harvard Apparatus RT (OTCQB: HRGN -$0.01 after Tuesday’s $0.00 and Monday’s $0.00))

 

The BOTTOM LINE:  Reiterating, “Tariff tolls” are beginning to loosen than clog the way forward … though continuous market appreciation bounces alternate sessions.

  • The president has signaled he's been paying attention to “market” noises, suggesting he may now be more focused on market reactions to his policies than before. Previously, the Trump administration claimed that it was not monitoring the stock market during the recent sell-off.
  • Also, Trump told reporters he has "no intention of firing" Fed Chair Powell, reversing a recent market narrative that had contributed to a nearly 1,000-point loss in the Dow on Monday.

 

I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader - him” – they were pretty simple instructions to follow!

 

Reiterating … My message, “The Trump administration … realizes drugs need to be made in America, not in foreign companies to be imported.

  • Also, most drug research is American based and if Kennedy slows or impedes their development or more – he will be bounced faster than a bond sell-off!!
  • Mark my words …!!

My perspective is to continue to nibble on sector equities, NO all ins – just add those with solid partners, lengthened runways and solid cash positions leveraged by solid management teams – there I see losses going forward!

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

I don’t have much to write/say other than “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.” <me>

 

April ‘25: understand the “flow” …

  • 4/23 – Wednesday closed positive with 22 positive, 10 negative and 3 flats
  • 4/22 – Tuesday closed positive with 30 positive, 3 negative and 2 flats
  • 4/21 - Monday closed positive with 21 positive, 13 negative and 1 flat
  • 4/18 – Friday, markets closed for Good Friday
  • 4/17 – Thursday closed positive with 25 positive, 7 negative and 3 flats
  • 4/16 – Wednesday closed negative with 2 positive, 31 negative and 2 flats
  • 4/15 – Tuesday closed barely positive with 17 positive, 16 negative and 2 flats
  • 4/14 - Monday closed positive with 23 positive, 7 negative and 5 flats
  • 4/11 – Friday closed positive with 28 positive, 5 negative and 2 flats
  • 4/10 – Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 4/9 – Wednesday closed positive with 33 positive, 1 negative and 1 flat
  • 4/8 - Tuesday closed negative with 4 positive, 30 negative and 1 flat
  • 4/7 - Monday closed negative with 13 positive, 20 negative and 2 flats
  • 4/4 – Friday closed negative with 3 positive, 30 negative and 2 flats
  • 4/3 – Thursday closed negative with 2 positive, 32 negative and 1 flat
  • 4/2 - Wednesday closed positive with 9 positive, 25 negative and 1 flat
  • 4/1 - Tuesday closed negative with 5 positive, 28 negative and 2 flats

 

What could 2025 have in store for the capital access space?

  • "You'll see a number of cell and gene therapy companies DESPARITE drive for financings – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in pipelines … capital expansion is second.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Wednesday: Alnylam Pharmaceuticals (ALNY), BioLife Solutions (BLFS) and Blueprint Medicine (BPMC)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and CRISPR Therapeutics (CRSP
  • Monday: Beam Therapeutics (BEAM), Regenxbio (RGNX) and Intellia Therapeutics (NTLA)

The worst three (3) in the session: 

  • Wednesday: Bluebird bio (BLUE), Intellia Therapeutics (NTLA) and Adverum Biotechnologies (ADVM)
  • Tuesday: Vericel (VCEL), Blueprint Medicine (BPMC) and Generation Bio (GBIO)
  • Monday: Alnylam Pharmaceuticals (ALNY), BioLife Solutions (BLFS) and Blueprint Medicine (BPMC)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.